Coherus Oncology
CHRS
156 hedge funds and large institutions have $271M invested in Coherus Oncology in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 48 increasing their positions, 54 reducing their positions, and 42 closing their positions.
164% more call options, than puts
Call options by funds: $3.15M | Put options by funds: $1.19M
8% less funds holding
Funds holding: 169 → 156 (-13)
10.97% less ownership
Funds ownership: 84.78% → 73.8% (-11%)
11% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 54
22% less capital invested
Capital invested by funds: $348M → $271M (-$76.3M)
24% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 42
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.03M |
| 2 |
Two Sigma Investments
New York
|
+$3.88M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.82M |
| 4 |
Barclays
London,
United Kingdom
|
+$2.97M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18M |
| 2 |
JP Morgan Chase
New York
|
-$13.2M |
| 3 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
-$8.76M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$5.88M |
| 5 |
Rafferty Asset Management
New York
|
-$3.28M |
CHRS Hedge Fund Activity: Q4 2023 in Review
156 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2023, worth a combined $271M — down 22% from $348M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of CHRS and 32 opened new positions — a net loss of 10 holders — while 54 trimmed existing stakes and 48 added.
The largest buyer was Millennium Management, adding an estimated $7.03M. The largest seller was State Street, cutting an estimated $18M.
- 156 institutional investors held Coherus Oncology (CHRS) as of Q4 2023, down from 169 in Q3 2023.
- Funds reported $271M of Coherus Oncology stock for Q4 2023, down 22% quarter-over-quarter.
- 32 funds opened new Coherus Oncology positions in Q4 2023 and 42 closed out, a net change of -10 holders.
- The largest Coherus Oncology buyer in Q4 2023 was Millennium Management, an estimated $7.03M added.
- The largest Coherus Oncology seller in Q4 2023 was State Street, an estimated $18M sold.
Based on aggregated 13F filings for Q4 2023.